Merrill maintains Replidyne at buy

Replidyne, Inc. was kept at a buy rating by Merrill Lynch analyst David Munno. The Food and Drug Administration will review Oscient's Factive for the treatment of acute bacterial sinusitis during the Sept. 11 week. The review is not expected to impact the analyst's view that Replidyne's Faropenem will be approved for the indication on or before Oct. 20, the PDUFA date. Shares of the Louisville, Ky.-based biopharmaceutical company were up 61 cents, or 6.46%, at $10.05. (Nasdaq: RDYN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.